ArticleScientific reports2026
Quercetin-4'-O-β-D-glucopyranoside inhibits ferroptosis though SIRT5-mediated desuccinylation of TFR1 in diabetic nephropathy.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sirtuin 5-mediated desuccinylation of PRDX6 inhibits ferroptosis and alleviates sepsis-associated acute kidney injury.Redox report : communications in free radical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic nephropathy (DN) is a severe complication of diabetes, marked by podocyte injury and renal dysfunction. Quercetin-4'-O-β-D-glucopyranoside (QODG), a flavonoid glycoside, has demonstrated renal protective effects. Succinylation, a post-translational modification, plays a critical role in cellular metabolism and disease progression. This study aimed to explore whether QODG alleviates DN by modulating SIRT5-mediated desuccinylation. Mouse podocyte clone-5 (MPC5) cells were exposed to high glucose (HG) with or without QODG treatment. Cell viability was measured using the cell counting kit-8 assay. Ferroptosis was assessed via commercial kits detecting lipid peroxidation and iron accumulation. Protein expression of ferroptosis- and succinylation-related markers was evaluated by Western blot. Immunoprecipitation combined with Western blot was used to detect succinylation levels of ferroptosis-related proteins. The interaction between SIRT5 and transferrin receptor 1 (TFR1) was examined by co-immunoprecipitation and proximity ligation assay assays. Additionally, an in vivo DN model was established in mice using high-fat diet and streptozotocin administration. High glucose induced ferroptosis in MPC5 cells, as indicated by increased lipid peroxidation, iron accumulation, and dysregulation of ferroptosis-related proteins. These effects were mitigated by QODG treatment. Mechanistically, QODG upregulated SIRT5 expression, which promoted desuccinylation of TFR1 at lysine 626 site, reducing its protein stability and inhibiting ferroptosis. Moreover, knockdown of SIRT5 aggravated ferroptosis and enhanced TFR1 succinylation, whereas overexpression of TFR1 counteracted the antiferroptotic effects of SIRT5. In DN mice, QODG ameliorated renal injury, oxidative stress, and ferroptosis. QODG inhibited ferroptosis by promoting SIRT5-mediated desuccinylation of TFR1, thereby attenuating DN. These findings highlight the potential of QODG as a therapeutic agent for DN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.